TY - JOUR
T1 - Biomaterial-based approaches to engineering immune tolerance
AU - Emerson, Amy E.
AU - Slaby, Emily M.
AU - Hiremath, Shivani C.
AU - Weaver, Jessica D.
N1 - Funding Information: Dr Jessica D. Weaver earned her PhD in Biomedical Engineering at the University of Miami. She completed a postdoctoral fellow- ship at the Georgia Institute of Technology, where she was sup- ported by the NIH ILET2 training grant and a JDRF Postdoctoral Fellowship. As an Assistant Professor in the School of Biological and Health Systems Engineering at Arizona State University, Dr Weaver’s research centers on developing translata ble cell-based therapies for the treatment of disease, with a focus on islet transplantation for the treatment of Type 1 Diabetes. The Weaver lab uses biomaterials and tolerogenic immunoengineering approaches with the aim to generate immunosuppression-free transplantation strategies. Publisher Copyright: © The Royal Society of Chemistry.
PY - 2020/12/21
Y1 - 2020/12/21
N2 - The development of biomaterial-based therapeutics to induce immune tolerance holds great promise for the treatment of autoimmune diseases, allergy, and graft rejection in transplantation. Historical approaches to treat these immunological challenges have primarily relied on systemic delivery of broadly-acting immunosuppressive agents that confer undesirable, off-target effects. The evolution and expansion of biomaterial platforms has proven to be a powerful tool in engineering immunotherapeutics and enabled a great diversity of novel and targeted approaches in engineering immune tolerance, with the potential to eliminate side effects associated with systemic, non-specific immunosuppressive approaches. In this review, we summarize the technological advances within three broad biomaterials-based strategies to engineering immune tolerance: nonspecific tolerogenic agent delivery, antigen-specific tolerogenic therapy, and the emergent area of tolerogenic cell therapy.
AB - The development of biomaterial-based therapeutics to induce immune tolerance holds great promise for the treatment of autoimmune diseases, allergy, and graft rejection in transplantation. Historical approaches to treat these immunological challenges have primarily relied on systemic delivery of broadly-acting immunosuppressive agents that confer undesirable, off-target effects. The evolution and expansion of biomaterial platforms has proven to be a powerful tool in engineering immunotherapeutics and enabled a great diversity of novel and targeted approaches in engineering immune tolerance, with the potential to eliminate side effects associated with systemic, non-specific immunosuppressive approaches. In this review, we summarize the technological advances within three broad biomaterials-based strategies to engineering immune tolerance: nonspecific tolerogenic agent delivery, antigen-specific tolerogenic therapy, and the emergent area of tolerogenic cell therapy.
UR - http://www.scopus.com/inward/record.url?scp=85098464203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098464203&partnerID=8YFLogxK
U2 - https://doi.org/10.1039/d0bm01171a
DO - https://doi.org/10.1039/d0bm01171a
M3 - Review article
C2 - 33179649
SN - 2047-4830
VL - 8
SP - 7014
EP - 7032
JO - Biomaterials Science
JF - Biomaterials Science
IS - 24
ER -